Histogen Stock Debt To Equity

HSTO Stock  USD 0.03  0.01  34.50%   
Histogen fundamentals help investors to digest information that contributes to Histogen's financial success or failures. It also enables traders to predict the movement of Histogen Stock. The fundamental analysis module provides a way to measure Histogen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Histogen stock.
Last ReportedProjected for Next Year
Debt To Equity 0.05  0.09 
As of the 23rd of November 2024, Debt To Equity is likely to grow to 0.09.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Histogen Company Debt To Equity Analysis

Histogen's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

 = 

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current Histogen Debt To Equity

    
  0.31 %  
Most of Histogen's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Histogen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Histogen Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Histogen is extremely important. It helps to project a fair market value of Histogen Stock properly, considering its historical fundamentals such as Debt To Equity. Since Histogen's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Histogen's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Histogen's interrelated accounts and indicators.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition

Histogen Total Stockholder Equity

Total Stockholder Equity

16.36 Million

At this time, Histogen's Total Stockholder Equity is very stable compared to the past year.
According to the company disclosure, Histogen has a Debt To Equity of 0.309%. This is 99.42% lower than that of the Biotechnology sector and 98.4% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.37% higher than that of the company.

Histogen Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Histogen's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Histogen could also be used in its relative valuation, which is a method of valuing Histogen by comparing valuation metrics of similar companies.
Histogen is currently under evaluation in debt to equity category among its peers.

Histogen Fundamentals

About Histogen Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Histogen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Histogen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Histogen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Histogen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Histogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Histogen will appreciate offsetting losses from the drop in the long position's value.

Moving against Histogen Stock

  0.6RNXT RenovoRxPairCorr
  0.46MDGL Madrigal PharmaceuticalsPairCorr
The ability to find closely correlated positions to Histogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Histogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Histogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Histogen to buy it.
The correlation of Histogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Histogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Histogen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Histogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Histogen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Histogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Histogen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Histogen Stock:
Check out Histogen Piotroski F Score and Histogen Altman Z Score analysis.
To learn how to invest in Histogen Stock, please use our How to Invest in Histogen guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Histogen. If investors know Histogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Histogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.81)
Revenue Per Share
0.004
Return On Assets
(0.54)
Return On Equity
(1.20)
The market value of Histogen is measured differently than its book value, which is the value of Histogen that is recorded on the company's balance sheet. Investors also form their own opinion of Histogen's value that differs from its market value or its book value, called intrinsic value, which is Histogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Histogen's market value can be influenced by many factors that don't directly affect Histogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Histogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Histogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Histogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.